255 related articles for article (PubMed ID: 12366816)
1. Glycosphingolipid lysosomal storage diseases: therapy and pathogenesis.
Jeyakumar M; Butters TD; Dwek RA; Platt FM
Neuropathol Appl Neurobiol; 2002 Oct; 28(5):343-57. PubMed ID: 12366816
[TBL] [Abstract][Full Text] [Related]
2. Metabolism of Glycosphingolipids and Their Role in the Pathophysiology of Lysosomal Storage Disorders.
Ryckman AE; Brockhausen I; Walia JS
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32961778
[TBL] [Abstract][Full Text] [Related]
3. Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin.
Platt FM; Neises GR; Reinkensmeier G; Townsend MJ; Perry VH; Proia RL; Winchester B; Dwek RA; Butters TD
Science; 1997 Apr; 276(5311):428-31. PubMed ID: 9103204
[TBL] [Abstract][Full Text] [Related]
4. Substrate reduction therapy for glycosphingolipid storage disorders.
Lachmann RH; Platt FM
Expert Opin Investig Drugs; 2001 Mar; 10(3):455-66. PubMed ID: 11227045
[TBL] [Abstract][Full Text] [Related]
5. New therapeutic prospects for the glycosphingolipid lysosomal storage diseases.
Platt FM; Butters TD
Biochem Pharmacol; 1998 Aug; 56(4):421-30. PubMed ID: 9763217
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapy.
Platt FM; Jeyakumar M; Andersson U; Priestman DA; Dwek RA; Butters TD; Cox TM; Lachmann RH; Hollak C; Aerts JM; Van Weely S; Hrebícek M; Moyses C; Gow I; Elstein D; Zimran A
J Inherit Metab Dis; 2001 Apr; 24(2):275-90. PubMed ID: 11405346
[TBL] [Abstract][Full Text] [Related]
7. Glycosphingolipid degradation and animal models of GM2-gangliosidoses.
Kolter T; Sandhoff K
J Inherit Metab Dis; 1998 Aug; 21(5):548-63. PubMed ID: 9728335
[TBL] [Abstract][Full Text] [Related]
8. N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal Sandhoff disease mice.
Baek RC; Kasperzyk JL; Platt FM; Seyfried TN
Neurochem Int; 2008 May; 52(6):1125-33. PubMed ID: 18207611
[TBL] [Abstract][Full Text] [Related]
9. Biochemistry of glycosphingolipid degradation.
Sandhoff K; Kolter T
Clin Chim Acta; 1997 Oct; 266(1):51-61. PubMed ID: 9435988
[TBL] [Abstract][Full Text] [Related]
10. Genetics and Therapies for GM2 Gangliosidosis.
Cachon-Gonzalez MB; Zaccariotto E; Cox TM
Curr Gene Ther; 2018; 18(2):68-89. PubMed ID: 29618308
[TBL] [Abstract][Full Text] [Related]
11. Multi-system disorders of glycosphingolipid and ganglioside metabolism.
Xu YH; Barnes S; Sun Y; Grabowski GA
J Lipid Res; 2010 Jul; 51(7):1643-75. PubMed ID: 20211931
[TBL] [Abstract][Full Text] [Related]
12. Biology and potential strategies for the treatment of GM2 gangliosidoses.
Chavany C; Jendoubi M
Mol Med Today; 1998 Apr; 4(4):158-65. PubMed ID: 9572057
[TBL] [Abstract][Full Text] [Related]
13. Neuronal Ganglioside and Glycosphingolipid (GSL) Metabolism and Disease : Cascades of Secondary Metabolic Errors Can Generate Complex Pathologies (in LSDs).
Sandhoff R; Sandhoff K
Adv Neurobiol; 2023; 29():333-390. PubMed ID: 36255681
[TBL] [Abstract][Full Text] [Related]
14. Miglustat: substrate reduction therapy for glycosphingolipid lysosomal storage disorders.
Lachmann RH
Drugs Today (Barc); 2006 Jan; 42(1):29-38. PubMed ID: 16511609
[TBL] [Abstract][Full Text] [Related]
15. Characterization of inducible models of Tay-Sachs and related disease.
Sargeant TJ; Drage DJ; Wang S; Apostolakis AA; Cox TM; Cachón-González MB
PLoS Genet; 2012 Sep; 8(9):e1002943. PubMed ID: 23028353
[TBL] [Abstract][Full Text] [Related]
16. The gangliosidoses: comparative features and research applications.
Baker HJ; Reynolds GD; Walkley SU; Cox NR; Baker GH
Vet Pathol; 1979 Nov; 16(6):635-49. PubMed ID: 116415
[TBL] [Abstract][Full Text] [Related]
17. Enhanced survival in Sandhoff disease mice receiving a combination of substrate deprivation therapy and bone marrow transplantation.
Jeyakumar M; Norflus F; Tifft CJ; Cortina-Borja M; Butters TD; Proia RL; Perry VH; Dwek RA; Platt FM
Blood; 2001 Jan; 97(1):327-9. PubMed ID: 11133779
[TBL] [Abstract][Full Text] [Related]
18. Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease.
Andersson U; Smith D; Jeyakumar M; Butters TD; Borja MC; Dwek RA; Platt FM
Neurobiol Dis; 2004 Aug; 16(3):506-15. PubMed ID: 15262262
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in the biochemistry of glycosphingolipid metabolism.
Kolter T; Doering T; Wilkening G; Werth N; Sandhoff K
Biochem Soc Trans; 1999 Aug; 27(4):409-15. PubMed ID: 10917612
[No Abstract] [Full Text] [Related]
20. [Molecular pathogenesis and therapeutic approach of GM2 gangliosidosis].
Tsuji D
Yakugaku Zasshi; 2013; 133(2):269-74. PubMed ID: 23370522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
